John T Lucas1, M Beth McCarville2, David A Cooper3, Mikhail Doubrovin2, Daniel Wakefield3, Teresa Santiago4, Yimei Li5, Xingyu Li5, Matthew Krasin6, Victor Santana7, Wayne Furman8, Andrew M Davidoff9. 1. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: john.lucas@stjude.org. 2. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Division of Radiation Oncology, University of Tennessee Health Science Center, Memphis, Tennessee. 4. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Department of Clinical Trials Administration, St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 9. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
PURPOSE: The predictive value of Image-Defined Risk Factors (IDRFs) developed by the International Neuroblastoma Risk Group Task Force as it relates to primary-site management is undefined and may aid patient selection for de-escalation of adjuvant radiation therapy to the primary site in high-risk neuroblastoma. METHODS AND MATERIALS: Patients (N = 76) with high-risk neuroblastoma treated on prospective trials at our institution from 1997 to 2014 were eligible for inclusion. IDRFs were defined based on pretherapy imaging. Overall survival, progression-free survival, and locoregional failure-free survival (LRFFS) were described using the Kaplan-Meier estimator and tested across strata by using the log-rank test. RESULTS: Twenty of 76 patients (26%) experienced local (n = 6), regional (n = 6), or combined locoregional failure (n = 8) with or without distant failure. Ten (50%) of the locoregional failures had concurrent distant relapse. Of patients who completed all therapy, both those with no IDRFs and those with >90% resection had a 3-year LRFFS of 100%, with or without radiation therapy. Patients with either ≥1 IDRF or <Gross Total Resection (GTR) or the inability to complete all therapy had inferior 3-year LRFFS of 77.8% and 14.4% with or without radiation therapy, respectively (P < .04). Patients treated with a dose ≥30.6 Gy as part of therapy for residual disease had an 83.3% locoregional control rate. CONCLUSIONS: Patients with >90% tumor resection and no primary site IDRFs at diagnosis may be candidates for de-escalation of adjuvant primary-site radiation therapy, although validation of these findings in future studies is required.
PURPOSE: The predictive value of Image-Defined Risk Factors (IDRFs) developed by the International Neuroblastoma Risk Group Task Force as it relates to primary-site management is undefined and may aid patient selection for de-escalation of adjuvant radiation therapy to the primary site in high-risk neuroblastoma. METHODS AND MATERIALS: Patients (N = 76) with high-risk neuroblastoma treated on prospective trials at our institution from 1997 to 2014 were eligible for inclusion. IDRFs were defined based on pretherapy imaging. Overall survival, progression-free survival, and locoregional failure-free survival (LRFFS) were described using the Kaplan-Meier estimator and tested across strata by using the log-rank test. RESULTS: Twenty of 76 patients (26%) experienced local (n = 6), regional (n = 6), or combined locoregional failure (n = 8) with or without distant failure. Ten (50%) of the locoregional failures had concurrent distant relapse. Of patients who completed all therapy, both those with no IDRFs and those with >90% resection had a 3-year LRFFS of 100%, with or without radiation therapy. Patients with either ≥1 IDRF or <Gross Total Resection (GTR) or the inability to complete all therapy had inferior 3-year LRFFS of 77.8% and 14.4% with or without radiation therapy, respectively (P < .04). Patients treated with a dose ≥30.6 Gy as part of therapy for residual disease had an 83.3% locoregional control rate. CONCLUSIONS: Patients with >90% tumor resection and no primary site IDRFs at diagnosis may be candidates for de-escalation of adjuvant primary-site radiation therapy, although validation of these findings in future studies is required.
Authors: Brian R Englum; Kristy L Rialon; Paul J Speicher; Brian Gulack; Timothy A Driscoll; Susan G Kreissman; Henry E Rice Journal: Pediatr Blood Cancer Date: 2015-03-23 Impact factor: 3.167
Authors: Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-11 Impact factor: 7.038
Authors: D Strother; J van Hoff; P V Rao; E I Smith; R C Shamberger; E C Halperin; K J Murray; R P Castleberry Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: Thomas E Merchant; Lan Nguyen; Duyen Nguyen; Shengje Wu; Melissa M Hudson; Sue C Kaste Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Daphne A Haas-Kogan; Patrick S Swift; Michael Selch; Gerald M Haase; Robert C Seeger; Robert B Gerbing; Daniel O Stram; Katherine K Matthay Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Christine Chung; Tom Boterberg; John Lucas; Joseph Panoff; Dominique Valteau-Couanet; Barbara Hero; Rochelle Bagatell; Christine E Hill-Kayser Journal: Pediatr Blood Cancer Date: 2021-05 Impact factor: 3.167
Authors: William C Temple; Kieuhoa T Vo; Katherine K Matthay; Brunilda Balliu; Christina Coleman; Jennifer Michlitsch; Andrew Phelps; Spencer Behr; Matthew A Zapala Journal: Cancer Med Date: 2020-12-13 Impact factor: 4.452
Authors: Jian-Guo Zhou; Bo Liang; Su-Han Jin; Hui-Ling Liao; Guo-Bo Du; Long Cheng; Hu Ma; Udo S Gaipl Journal: Front Oncol Date: 2019-12-04 Impact factor: 6.244